March 4th 2024
A new study points to disparities for patients in respiratory failure, which can have dire consequences. The lead researchers talk about the implications.
Payer issues with new heart failure drug
August 18th 2015Entresto is the first in a new class of drugs, valsartan combined with sacubitril, a pro-drug of a compound that is a receptor‐neprilysin inhibitor (ARNI). It is taken orally twice daily. It was approved for heart failure patients with reduced ejection fraction based on the PARADIGM-HF trial.
Read More